Entity type
Company
Filer Snapshot
ASTRAZENECA PLC
CIK 0000901832. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.
Total filings
9
Latest filing
22 May 2026
Industry
Pharmaceutical Preparations
Filing-backed research brief
Start with the SEC data that changes for this CIK
Latest signal: 13D/G stake for MNPR. Each card links back to the PortfolioSavvy page where the filing evidence is closest.
Latest 13F portfolio
—
No parsed 13F portfolio row yet.
Browse latest 13FLargest parsed holding
—
Populates from the latest parsed 13F information table.
Open holding13D/G large stake
MNPR
31 Dec 2025 · 7.8% ownership
Open 13D/GInsider / owner context
—
No parsed Forms 3/4/5 owner position for this CIK.
Browse insider filingsSave this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Source: SEC Forms 3/4/5
View source filing
4 filed on 22 May 2026 for CIK 0000901832.
- Listed symbols
- AZN on NYSE
- Parsed SEC ownership signals
-
Largest active 13D stakes
Active large-stake positions disclosed in parsed Schedule 13D filings.
CLLS Innate Pharma SALargest active 13G stakes
Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.
MNPR CDTHow to read these SEC ownership signals
- Read each filing family separately: 13F portfolios, 13D/G large stakes, and Forms 3/4/5 owner positions answer different SEC disclosure questions.
- Open the linked research path when you need the filing, CIK, issuer, or CUSIP trail behind a value.
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA
- Incorporated in
- United Kingdom
- Fiscal year end
- 31 December
- Former names on EDGAR
- ZENECA GROUP PLC (to 05 Feb 1999)
Ownership signals
CIK-linked ownership evidence from parsed SEC filings.
1 signal
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Filer intelligence
What SEC filings say about ASTRAZENECA PLC
A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.
Quick read
- 4 recent 13D/G stake rows found; top row is MNPR at 7.8% ownership.
SEC source mix
Counts show available parsed rows, not one combined ownership total.
13D/G large-stake context
MNPR
31 Dec 2025 · Common Stock, $0.001 par value per share
Innate Pharma SA
22 Dec 2025 · Ordinary Shares, EUR0.05 nominal value per share
CDT
31 Mar 2025 · Common Stock, par value $0.0001 per share
CLLS
23 Jan 2025 · Ordinary shares, nominal value of EUR0.05 per ordinary share
Latest update
What changed recently for ASTRAZENECA PLC
Latest financial period: Q4 2025. Open the source-backed page to inspect the fresh filing or facts context.
Update date
24 Feb 2026
Page type
Company facts
Latest period
Q4 2025
SEC-backed company facts were refreshed from filings filed on 24 Feb 2026.
Benchmark Context
Benchmark context for this company
ASTRAZENECA PLC has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.
Compared with
Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.
Why this is notable
Latest financial period: Q4 2025. That gives you a fresh baseline before you compare this company with peers.
- Latest company facts filing date: 24 Feb 2026.
- Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
- Open the facts page first if you want the cleanest path to verification.
Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.
SEC filing record
CIK 0000901832 filing coverage
Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.
SEC filings
9
First seen
24 Jan 2025
Latest filing
22 May 2026
Entity
Company
Observed form types
20-F
3
4
SCHEDULE 13D/A
SCHEDULE 13G/A
Industry context: Pharmaceutical Preparations.
Latest Filings
Showing the latest 9 of 9 SEC filings for ASTRAZENECA PLC.
4
4 filing
- Filing date
- 22 May 2026
- Reporting date
- 20 May 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 08 May 2026
- Reporting date
- 07 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
3
3 filing
- Filing date
- 19 Mar 2026
- Reporting date
- 18 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
20-F
20-F filing
- Filing date
- 24 Feb 2026
- Reporting date
- 31 Dec 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SCHEDULE 13G/A
SCHEDULE 13G/A filing
- Filing date
- 06 Feb 2026
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SCHEDULE 13D/A
SCHEDULE 13D/A filing
- Filing date
- 06 Feb 2026
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SCHEDULE 13G/A
SCHEDULE 13G/A filing
- Filing date
- 10 Apr 2025
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
20-F
20-F filing
- Filing date
- 18 Feb 2025
- Reporting date
- 31 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SCHEDULE 13D/A
SCHEDULE 13D/A filing
- Filing date
- 24 Jan 2025
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing